Please assess the completion status of the following clinical trial:

Trial Title: A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients undergoing flexible bronchoscopy~* Hemodynamic stability~Exclusion Criteria:~* Patients receiving sedatives during the course of their treatment~* Patients undergoing conventional TBNA and/or EBUS-TBNA who are likely to receive sedation~* Patients with known hypersensitivity to lignocaine~* Not willing to provide informed consent

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1% lignocaine (Type: EXPERIMENTAL): Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.
- 2% lignocaine (Type: ACTIVE_COMPARATOR): Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).